May 2013, Vol 2, No 3

← Back to Issue

Personalized Medicine in Oncology: Providing Insights to Optimally Utilize Personalized Medicine Concepts

Greg Kalemkerian, MD


Dear Colleague,

I want to welcome you to this issue of Personalized Medicine in Oncology (PMO) with a few facts concerning personalized medicine (PM):

  • 79% of late-stage oncology pipeline are targeted therapies
  • Molecular profiling is driving many new targeted cancer therapeutics, with over 500 compounds coming soon, and 140 targets in development
  • Companion diagnostics are playing an increasingly greater role in cancer product launches

Taken alone, any of these developments would call for intensified efforts to educate practicing oncologists in PM systems and resources. Taken together, they are a clarion call for extraordinary measures to ensure that this happens.

PM is a medical art form requiring awareness of key diagnostic and therapeutic resources. The demand for excellence by patients and caregivers is matched by the demand for value by payers and purchasers. All of these parties recognize cancer as the deadly enemy and will go to great lengths to obtain patient-
centered, value-based care.

Enter PMO. We bring oncologists the insights into the key developments in PM needed to raise their clinical skills and stay competitive through the expert use of the breakthrough treatments and diagnostics. The greatest clinical armamentarium is meaningless without knowledge of its proper deployment…and that is what PMO brings to oncologists in every issue. Our balanced reviews and editorials give today’s oncologists the insight they need to optimally utilize the products that bring value to the patient-centered cancer care model that is taking shape before our eyes.


Greg Kalemkerian, MD
University of Michigan
PMO Board Member

Uncategorized - May 24, 2013

Sequential Therapy for Renal Cell Carcinoma

With several agents now approved and broadly available for the treatment of patients with advanced renal cell carcinoma (RCC), a great deal of attention has been focused on determining the most appropriate sequence of therapies. The concept of sequential therapy has developed for several reasons, including: 1) The availability of [ Read More ]

Uncategorized - May 24, 2013

Higher HER2 Expression Leads to Better Outcomes With T-DM1 in HER2-Positive Metastatic Breast Cancer

Among women with HER2-positive metastatic breast cancer, those with the highest expression of HER2 had the best outcomes on treatment with T-DM1, according to a biomarker analysis of the phase 3 EMILIA trial presented at the American Association for Cancer Research 2013 Annual Meeting. Further, the analysis found that T-DM1 [ Read More ]